eleclazine   Click here for help

GtoPdb Ligand ID: 8413

Synonyms: GS-6615 | GS6615
Compound class: Synthetic organic
Comment: Eleclazine is a sodium channel inhibitor, modulating cardiac late Na+ currents via the Nav1.5 (gene symbol SCN5A) channel. The compound is a dihydrobenzodiazepine type structure. Dihydrobenzodiazepine scaffolds are being developed as α-helix mimetics, with the potential to inhibit protein-protein interactions [1,3-5]. This chemical structure and its use is covered by patent US20150038489 [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 64.55
Molecular weight 415.11
XLogP 3.89
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C1N(CCOc2c1cc(cc2)c1ccc(cc1)OC(F)(F)F)Cc1ncccn1
Isomeric SMILES O=C1N(CCOc2c1cc(cc2)c1ccc(cc1)OC(F)(F)F)Cc1ncccn1
InChI InChI=1S/C21H16F3N3O3/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19/h1-9,12H,10-11,13H2
InChI Key YNUAEEJQYHYLMS-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Eleclazine (under its research code GS-6615) is being evaluated in Phase 2I clincal trials as a potential treatment for long QT-3 (LQT3) syndrome and hypertrophic cardiomyopathy. Phase 2 trials for chronic stable angina and coronary artery disease, and ventricular arrhythmia are underway. In May 2015, the US FDA granted eleclazine (under its IUPAC name) orphan drug designation for the treatment of congenital long QT syndrome.